<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562740</url>
  </required_header>
  <id_info>
    <org_study_id>ABLUMINUS BTK</org_study_id>
    <nct_id>NCT04562740</nct_id>
  </id_info>
  <brief_title>ABLUMINUS DES BTK Registry - FIM</brief_title>
  <official_title>ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) - First in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concept Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concept Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single center, single arm non-randomized trial collecting safety and&#xD;
      effectiveness data for the ABLUMINUS DES System to treat BTK lesions in subjects with CLI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this&#xD;
      problem is set to worsen globally with increasing prevalence of diabetes. Treatment of PAD in&#xD;
      diabetic critical limb ischemia (CLI) primarily involves revascularisation of the limb.&#xD;
      Angioplasty as a first line strategy of revascularization over surgical procedures has been&#xD;
      adopted by most vascular centers.&#xD;
&#xD;
      Arterial blockages for diabetic CLI patients occur predominantly in below the knee arteries&#xD;
      which can be challenging to treat effectively. This is due to the high incidence of arterial&#xD;
      recoil after conventional balloon angioplasty due the natural tendency of the vessels to&#xD;
      maintain their original shape and the high restenosis rates of calcified lesions.&#xD;
&#xD;
      To address these problems the novel ABLUMINUS DES system is specifically designed to&#xD;
      withstand the mechanical recoil of diseased BTK arteries whilst delivering sirolimus to&#xD;
      biologically inhibit restenosis.&#xD;
&#xD;
      This study postulates that the application of the ABLUMINUS DES system will be safe and will&#xD;
      result in better vascular patency in BTK arteries for CLI patients.&#xD;
&#xD;
      The investigators aim to conduct a prospective, all comers, single arm, single centre&#xD;
      registry of the ABLUMINUS DES system for the treatment of BTK disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">December 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>During the index angioplasty revascularisation procedure of the limb salvage programme, the ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency using duplex ultrasound at 6 months post-procedure</measure>
    <time_frame>at 6 months post-procedure</time_frame>
    <description>Number of Primary patency using duplex ultrasound at 6 months post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse events (MAE) at 6 months post-procedure</measure>
    <time_frame>at 6 months post-procedure</time_frame>
    <description>Number of Major adverse events (MAE) (MAE is defined as above ankle amputation in index limb; major re-intervention; and perioperative (30 day) mortality)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary and assisted primary patency</measure>
    <time_frame>6, 12, 24 months post procedure</time_frame>
    <description>Target lesion patency rate measured by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization</measure>
    <time_frame>1, 3, 6, 12, 24 months post procedure</time_frame>
    <description>Number of Clinically-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation rates</measure>
    <time_frame>1, 3, 6, 12, 24 months post procedure</time_frame>
    <description>Rates of amputation of the lower limb at the ankle level or above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject quality-of-life values by change in EQ-5D (EuroQol 5 dimension)</measure>
    <time_frame>1, 3, 6 and 12 months post procedure</time_frame>
    <description>The EQ-5D is a descriptive system of health-related quality-of-life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension). The levels are assigned a numeric code 1-5 (eg, 1= no problems and 5= extreme problems). Sub-scores are not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Assessment</measure>
    <time_frame>1, 3, 6, 12, 24 months post procedure</time_frame>
    <description>Descriptive characteristics of wound healing will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>3, 6, 12, 24 months post procedure</time_frame>
    <description>Change in Rutherford classification as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1, 3, 6, 12, 24 months post procedure</time_frame>
    <description>Number of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospital readmission</measure>
    <time_frame>Up to 30 days post procedure</time_frame>
    <description>Unplanned hospital related to Critical Limb Ischemia readmission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>6, 12, 24 months years post procedure</time_frame>
    <description>Number of patients with all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic outcomes</measure>
    <time_frame>6 and 12 months post procedure</time_frame>
    <description>Changes in ankle brachial index (ABI) and/or Toe pressures (TP</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Arterial Disease of Legs</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>ABLUMINUS DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.&#xD;
Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABLUMINUS DES drug eluting stent</intervention_name>
    <description>Following successful plain balloon angioplasty of the arterial lesion, (defined as &lt;30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.</description>
    <arm_group_label>ABLUMINUS DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 21 years or older and has signed and dated the trial informed consent&#xD;
             document (ICD)&#xD;
&#xD;
          2. Subject is willing and able to comply with the trial testing, procedures and follow-up&#xD;
             schedule&#xD;
&#xD;
          3. Subject has chronic, symptomatic diabetic related lower limb ischemia, determined by&#xD;
             Rutherford categories 4 to 6 in the target limb, with wound(s) confined to&#xD;
             toes/forefoot&#xD;
&#xD;
          4. Subject is a male or non-pregnant female. If female of child-bearing potential, and if&#xD;
             sexually active must be using, or agree to use, a medically-acceptable method of birth&#xD;
             control as confirmed by the investigator&#xD;
&#xD;
        Intraoperative inclusion criteria&#xD;
&#xD;
        11. Stenotic, restenotic or occlusive target lesion(s) located in the tibioperoneal trunk,&#xD;
        anterior tibial, posterior tibial and/or peroneal artery(ies).&#xD;
&#xD;
        12. Target lesion(s) must be at least 4cm above the ankle joint&#xD;
&#xD;
        13. A single target lesion per vessel, in up to 2 vessels, in a single limb&#xD;
&#xD;
        14. Degree of stenosis ≥ 70% by visual angiographic assessment&#xD;
&#xD;
        15. RVD is between 2.5 - 3.75mm&#xD;
&#xD;
        16. Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm&#xD;
        (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents)&#xD;
&#xD;
        17. Target vessel(s) reconstitute(s) at or above the stenting limit zone (4cm above the&#xD;
        ankle joint)&#xD;
&#xD;
        18. Target lesion(s) is located in an area that may be stented without blocking access to&#xD;
        patent main branches&#xD;
&#xD;
        19. Treatment of all above the knee inflow lesion(s) is successful prior to treatment of&#xD;
        the target lesion&#xD;
&#xD;
        20. Guidewire has successfully crossed the target lesion(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy ≤ 1year&#xD;
&#xD;
          2. Stroke ≤ 90 days prior to the procedure date&#xD;
&#xD;
          3. Prior or planned major amputation in the target limb&#xD;
&#xD;
          4. Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass)&#xD;
&#xD;
          5. Previously implanted stent in the target vessel(s)&#xD;
&#xD;
          6. Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date&#xD;
&#xD;
          7. Heel gangrene&#xD;
&#xD;
          8. Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure&#xD;
             date&#xD;
&#xD;
          9. NYHA class IV heart failure&#xD;
&#xD;
         10. Subject has symptomatic coronary artery disease (ie, unstable angina)&#xD;
&#xD;
         11. History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date&#xD;
&#xD;
         12. Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease,&#xD;
             vasculitis)&#xD;
&#xD;
         13. Subject is currently taking Canagliflozin&#xD;
&#xD;
         14. Body Mass Index (BMI) &lt;18&#xD;
&#xD;
         15. Active septicemia or bacteremia&#xD;
&#xD;
         16. Coagulation disorder, including hypercoagulability&#xD;
&#xD;
         17. Contraindication to anticoagulation or antiplatelet therapy&#xD;
&#xD;
         18. Known allergies to stent or stent components&#xD;
&#xD;
         19. Known allergy to contrast media that cannot be adequately pre-medicated prior to the&#xD;
             interventional procedure&#xD;
&#xD;
         20. Known hypersensitivity to heparin&#xD;
&#xD;
         21. Subject is on a high dose of steroids or is on immunosuppressive therapy&#xD;
&#xD;
         22. Subject is currently participating, or plans to participate in, another&#xD;
             investigational trial that may confound the results of this trial (unless written&#xD;
             approval is received from the Concept Medical study team)&#xD;
&#xD;
        Intraoperative exclusion criteria&#xD;
&#xD;
          1. Angiographic evidence of intra-arterial acute/subacute thrombus or presence of&#xD;
             atheroembolism&#xD;
&#xD;
          2. Treatment required in &gt; 2 target vessels (Note: a target lesion originating in one&#xD;
             vessel and extending into another vessel is considered 1 target vessel)&#xD;
&#xD;
          3. Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s),&#xD;
             (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy)&#xD;
&#xD;
          4. Aneurysm is present in the target vessel(s)&#xD;
&#xD;
          5. Extremely calcified lesions&#xD;
&#xD;
          6. Failure to obtain &lt;30% residual stenosis in a pre-existing lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edward Choke</last_name>
    <phone>65 69302164</phone>
    <email>edward.choke.t.c@singhealth.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edward Choke</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sengkang General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>544886</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Choke, Dr</last_name>
      <email>edward.choke.t.c@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008 May;47(5):975-981. doi: 10.1016/j.jvs.2008.01.005. Epub 2008 Apr 18.</citation>
    <PMID>18372148</PMID>
  </reference>
  <reference>
    <citation>Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC, Tsolakis J. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009 Sep;20(9):1141-50. doi: 10.1016/j.jvir.2009.05.031. Epub 2009 Jul 19.</citation>
    <PMID>19620014</PMID>
  </reference>
  <reference>
    <citation>Biondi-Zoccai GG, Sangiorgi G, Lotrionte M, Feiring A, Commeau P, Fusaro M, Agostoni P, Bosiers M, Peregrin J, Rosales O, Cotroneo AR, Rand T, Sheiban I. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther. 2009 Jun;16(3):251-60. doi: 10.1583/09-2691.1. Review.</citation>
    <PMID>19642789</PMID>
  </reference>
  <reference>
    <citation>Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005 Mar;41(3):423-35; discussion 435.</citation>
    <PMID>15838475</PMID>
  </reference>
  <reference>
    <citation>Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, Krankenberg H, Baumgartner I, Siablis D, Lammer J, Van Ransbeeck M, Qureshi AC, Stoll HP; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012 Dec 4;60(22):2290-5. doi: 10.1016/j.jacc.2012.08.989.</citation>
    <PMID>23194941</PMID>
  </reference>
  <reference>
    <citation>Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, Schmidt A, Tessarek J, Vinck E, Schwartz LB. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012 Feb;55(2):390-8. doi: 10.1016/j.jvs.2011.07.099. Epub 2011 Dec 14.</citation>
    <PMID>22169682</PMID>
  </reference>
  <reference>
    <citation>Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E, Sixt S, Schwarz T, Brechtel K, Böhme C, Neumann FJ, Zeller T. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011 Sep;32(18):2274-81. doi: 10.1093/eurheartj/ehr144. Epub 2011 May 26.</citation>
    <PMID>21622669</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>DES</keyword>
  <keyword>PAD</keyword>
  <keyword>PTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

